P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

CUBIST: A NEW PROMISING COLLABORATION

regi98test12

Date: 19 Mar 2008
Time: 22:35:34

Comments

regi98test12

Date: 28 Jun 2001
Time: 11:05:21

Comments

Cambridge, MA and San Diego, CA, June 27, 2001 -- Cubist Pharmaceuticals, Inc. (CBST) and Syrrx, Inc., a privately held company, today announced the formation of an antiinfective drug discovery collaboration. The joint effort will use Syrrx and Cubist technologies for the high-throughput characterization of novel antiinfective drug targets and rational drug design. As a result of the collaboration, the companies expect to accelerate the discovery of novel classes of antibiotics to treat infectious diseases, including those resistant to current therapies. Financial incentives for the collaboration include research and clinical milestones, royalties and an upfront equity investment in Syrrx by Cubist.

Syrrx's technology platform systematically bypasses historical bottlenecks in the classical protein structure determination process. Deployed in a streamlined, factory-like environment, Syrrx's automated systems enable the high-throughput determination of protein structures more reliably and economically than previously thought possible. This capability is used in combination with computational drug discovery approaches to identify novel drug candidates.

Syrrx will work to determine the three-dimensional structure of certain antiinfective targets identified through Cubist discovery efforts. The majority of these targets have been derived from bacterial genes of interest and have been validated to be essential for bacterial survival. As structures are determined, targets will enter a structure-based drug-design phase to screen for potential pharmaceuticals. Cubist and Syrrx will then determine whether drug candidates will enter into medicinal chemistry programs. These programs will be conducted either jointly or separately by each company, as specified in the agreement.

"We are very pleased to be entering into this alliance with Cubist," said Wendell Wierenga, Ph.D., CEO of Syrrx. "We believe it is the first structural proteomics deal of its kind and scope, given the large number of antiinfective drug targets subject to parallel discovery efforts. With Syrrx's high-throughput capabilities and Cubist's experience in antiinfectives and rational drug design, we hope to demonstrate that rational drug discovery is a scalable paradigm. Our deal with Cubist," Dr. Wierenga added, "is the first of what we expect to be a series of similar research and discovery collaborations in a number of therapeutic areas." George "Skip" Shimer, Ph.D., Vice President of Research at Cubist commented, "We feel this deal with Syrrx to be an ideal leveraging of both companies' strengths. Specifically, we believe the synergies between Syrrx's structural proteomics platform and both our VITA™ technology, which identifies novel antiinfective targets, and our ChemInformatics technology, which facilitates the design of novel antiinfectives, should allow us to advance multiple candidates into medicinal chemistry programs. We are hopeful that these programs will contribute significantly to our growing antiinfective product pipeline."

Cubist Pharmaceuticals, Inc. is focused on becoming a global leader in the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections. Cubist is evaluating the safety and efficacy of Cidecin™ (daptomycin for injection) in the EDGE™ (Evaluation of Daptomycin against Gram-positive Entities) clinical trial program and has broadened its pipeline to include multiple pre-clinical drug candidates.

The Company is engaged in strategic partnerships with Novartis Pharma AG and Merck & Co., Inc. for the discovery and development of novel antiinfectives and with Gilead Sciences for the commercialization of daptomycin in Europe. Cubist is headquartered in Cambridge, MA and has operations in Vancouver, BC, Canada and Slough, UK.

Syrrx, Inc. is a San Diego biotechnology company shaping the future of drug discovery. The company is the technological leader in the field of structural proteomics, the process of generating protein structures from genetic information. Syrrx uses its proprietary technologies to rapidly generate protein structures for the discovery of new drugs. This process enables a unique "gene to drug" platform based on the ability to perform high-throughput rational drug discovery.

Cubist Safeharbor Statement

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by the Company. These factors include, but are not limited to:

(i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization;

(ii) the Company's ability to obtain required governmental approvals;

(iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed on April 2, 2001.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName